CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal... Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.
- Mechanism
- Curator reviewed
CHF 4227 binds with high affinity to the human estrogen receptor-alpha and beta. It compares favorably in efficacy and potency with raloxifene in preventing bone loss and in antagonizing EE2 stimulation of the uterus. This attribute along with the minimal uterine stimulation suggests a therapeutic advantage to CHF 4227 over EE2 or raloxifene for the treatment of postmenopausal women.
- Primary indication
- Investigated for use/treatment in osteoporosis.Curator reviewed
- Code names
- CHF 4227
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with CHF 4227, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account